Verastem (VSTM)
(Delayed Data from NSDQ)
$2.96 USD
-0.01 (-0.34%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.97 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 121 - 140 ( 266 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Copiktra Ramp Slower Than Expected; Adjusting PT to $10.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
California Dreamin? I: Biotech Stories To Keep An Eye On
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Steady Ramp for Copiktra Sales; Addition to NCCN Guidelines for MZL; Adjusting PT to $13.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Copiktra Off to an Encouraging Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Copiktra Licensed to CSPC in China; We See Potential for an Accelerated Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Now With an Approved Oncology Drug; Reiterate Buy - Raising PT to $14
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Duvelisib Approved for All Three Indications; Higher $15.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Duvelisib PDUFA Date; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - ORD-ARN-JFK: Crossing Our Onco Radar
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Watch Dilution and Competition; Maintain Buy - Lowering PT to $10
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Duvelisib Partnered in Japan; Promising ASCO Results Highlight Future Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Updates on Defactinib and Duvelisib Programs at ASCO 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Our Takeaways From Verastem Investor Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S